Open Orphan is targeting a valuation of €100 million in the next year after it completes the reverse takeover of drug services company Venn Life Sciences.
Open Orphan is currently in the middle of a fundraising round with the company seeking a modest amount of new cash, understood to be less than €10 million, from investors, according to market sources. The company and its advisers, IBI Corporate Finance, met with potential new investors in London...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team